Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents
Inventors
Mandel, Arkady • Dumoulin-White, Roger
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11813330-B2
Publication Date
2023-11-14
Expiration Date
Abstract
A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a sonosensitizing compound containing at least one transition metal with three bidentate ligands; and (b) exposing the sonosensitizing compound in the organism to ultrasound, wherein the ultrasound is effective to activate the sonosensitizing compound to destroy at least one of the cells and the microorganisms in the organism. The ultrasound is preferably used in conjunction with electromagnetic therapies comprising photodynamic therapy, low-level laser therapy, and radiation therapy. The ultrasound is preferably administered at a duty cycle in the range from 5% to 95% at a power density of 10 W/cm2 and a frequency in the range from 10 Hz to 10 MHz.
Core Innovation
The invention relates to a method for damaging a target material in an organism by administering a composition comprising a sonosensitizing compound and then exposing the sonosensitizing compound to an activating energy. The activating energy comprises ultrasound effective to trigger the sonosensitizing compound to damage the target material, and the target material comprises at least one of cells and microorganisms.
The sonosensitizing compound is defined by formula (I), wherein M is osmium or ruthenium and X is selected from Cl−, PF6−, Br−, BF4−, ClO4−, CF3SO3−, and SO4^2−. The formula further specifies values of q, y, and z, with q+y+z=3, and includes bidentate ligands Lig1, Lig2, and Lig3 with stated substituent selections.
The disclosure further states that the sonosensitizing compound has a structure selected from hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof. Ultrasound is used as the activating energy effective to trigger the sonosensitizing compound to damage the target material comprising at least one of cells and microorganisms.
Claims Coverage
The partial claim set includes two independent claims. Across the independent claims, the inventive coverage centers on administering a composition comprising a sonosensitizing compound and using ultrasound as activating energy to trigger damage of at least one of cells and microorganisms, with one claim limited by formula (I) and the other by a selected compound structure.
Ultrasound-activated damage using an osmium or ruthenium sonosensitizing compound of formula (I)
Administering to the organism a composition comprising a sonosensitizing compound having formula (I), wherein M is osmium or ruthenium, X is selected from Cl−, PF6−, Br−, BF4−, ClO4−, CF3SO3−, and SO4^2−, and the compound includes bidentate ligands Lig1, Lig2, and Lig3; then exposing the sonosensitizing compound to activating energy comprising ultrasound effective to trigger damage of the target material, with the target material comprising at least one of cells and microorganisms.
Ultrasound-activated damage using a structure-selected sonosensitizing compound
Administering to the organism a composition comprising a sonosensitizing compound having a structure selected from the group consisting of hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and exposing the sonosensitizing compound to activating energy comprising ultrasound effective to trigger damage of the target material, with the target material comprising at least one of cells and microorganisms.
Both independent claims cover ultrasound activation of a sonosensitizing compound to damage at least one of cells and microorganisms. One independent claim is defined by formula (I) with osmium or ruthenium and specified anions and ligands, while the other is defined by a structure selected from hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes.
Stated Advantages
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?